INVION PRESENTS DATA TO US MARKET

INVION PRESENTS DATA TO US MARKET

RESPIRATORY technology company Invion Limited (ASX:IVX) has delivered findings from its trial of oral nadolol to international medical experts at a conference in the US.

The Brisbane-based company attended the American Thoracic Society (ATS) meeting to present data from its ongoing study of INV102.

The trial uses the lead compound to assist patients experiencing chronic cough while attempting to give up cigarettes.

Early results show that key signs of respiratory inflammation could be reduced in four weeks of treatment, as opposed to the placebo.

Lead study investigators Dr Mario Castro and Geneline Sajol from Washington University say they decided to open the trial to patients without chronic obstructive pulmonary disorder (COPD).

Oral nadolol could be safely administered to patients with "smokers cough" as well as cases of COPD.

"On examining baseline biomarkers, we found no difference in COPD versus non-COPD subjects," Castro says.

"What this essentially means is that we now believe we can safely target the smoking population with or without diagnosed COPD, because of the similarities in airway inflammation."

Nadolol is currently used to treat high blood pressure and migraine. Invion is repurposing the drug to treat asthma and COPD.

The global market opportunity for inflammatory airway disease treatment is estimated to be worth $34 billion.

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

How citizen developers can help save Australian businesses from IT skills shortage
Partner Content
Warnings from business leaders across Australia, including Coles CEO Steven Cain, have ...
Mendix
Advertisement

Related Stories

Fitness First parent divests franchise division of Jetts Fitness via management buyout

Fitness First parent divests franchise division of Jetts Fitness via management buyout

Jetts Fitness Australia CEO Elaine Jobson has led the acquisition o...

Universal Store buys Byron Bay fashion brand THRILLS for $50m

Universal Store buys Byron Bay fashion brand THRILLS for $50m

After working alongside Universal Store (ASX: UNI) for nine years, ...

Superloop seizes on education recovery with $50m deal for student broadband provider VostroNet

Superloop seizes on education recovery with $50m deal for student broadband provider VostroNet

Bevan Slattery-founded internet infrastructure provider Superl...

Hogg quits as The Star’s acting CEO just days ahead of Queensland casino inquiry findings

Hogg quits as The Star’s acting CEO just days ahead of Queensland casino inquiry findings

The depletion of The Star Entertainment Group’s (ASX: SGR) ex...